|Day Low/High||41.81 / 42.20|
|52 Wk Low/High||37.20 / 45.58|
Wall Street's first glimpse at the second quarter.
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced a submission to the European Medicines Agency (EMA) for the extended use of once-daily Relvar Ellipta (fluticasone furoate/vilanterol,...
The collapse of the Sino-American session on tariffs and access translates into market action for investors, and inaction on improved trade.
Hikma shares were active in London trading Monday after the drugmaker unveiled a reorganization of its U.S. business that includes a change in leadership.
Commodity markets, economic growth and the potential for a broad tightening of monetary policy in the developed world over the coming quarters recaptured investors' attention Thursday.
Developing a promising drug? This new investment fund is looking to invest in Phase 2 candidates.
While causing upset among politicians and some business leaders, President Donald Trump's withdrawal of the U.S. from the Paris Agreement helped boost stock prices across the chemicals and automotive sectors.
Glaxo was boosted Friday after its HIV joint-venture filed an application in the U.S. and EU for a new combination tablet, in a continued push for dominance in the field
GSK is trading at 2017 highs today as investors continue to aggressively accumulate shares.
European stocks were mixed Wednesday as investors responded to a mixture of M&A speculation, economic data and other individual company news.
Arrary reacquired MEK inhibitor in 2015 as part of FTC settlement with Novartis.
European stocks fell Tuesday as politics returned to forefront of investors' minds, with election talk in Italy and the U.K., and renewed transatlantic sabre rattling, all taking centre stage.
GlaxoSmithKline shares outperformed the market Tuesday after clinical trials data for Gilead's Bictegravir HIV treatment appeared to reduce the threat of a superior rival to GSK's Dolutegravir.
A head-to-head showdown in metastatic breast cancer and the Roche APHINITY data are next key events for Puma.
The latest earnings from two of the largest generic drug makers show how important it is for generic firms to have their own stable of higher-margin branded products.
Here are Tuesday's top research calls, including new coverage of recent IPOs Cloudera and Carvana, as well as new analyst coverage of Domino's Pizza and an upgrade of McKesson.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BKFS, CWAY, DE, EZPW, GSK, LMNX Downgrades: AMC, ESRT, MYOK, WERN Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
Hikma Pharmaceuticals lowered its full year revenue guidance Friday after the U.S. Food & Drug Administration expressed concern over its generic Advair Diskus product.
Hikma could get hit with sizeable downgrades Friday when it updates the market with new guidance in the wake of the FDA's rejection of its generic Advair Diskus product
Novartis holds a 36.5% stake in the healthcare company.
GlaxoSmithKline shares traded firmly higher Friday after one of its biggest shareholders said he was dumping his holding after fifteen years out of "frustration".
Hikma shares plunged the most in nine months inLondon trading Thursday after the drugmaker said that approval of its generic Advair Diskus asthma treatment faces delays from the FDA.
European stock markets were mixed Wednesday's as investors responded to yet another raft earnings reports, company statements and comments from policy makers across the continent.
Earlier this year the FDA sent Mylan a letter saying it would not approve its drug.
Hikma Pharmaceuticals fell sharply in London ahead of a crucial decision by the U.S. Food & Drug Administration on whether to approve its generic Advair asthma treatment.
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva Inc (NASDAQ: INVA) today announced positive results from the innovative Salford Lung Study (SLS) in asthma, carried out amongst 4,233 patients treated by their own General...
Stocks move mostly lower on Thursday after the House passes a bill to repeal and replace the Affordable Care Act.